FRLN - Freeline Therapeutics Holdings plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2200
-0.0400 (-1.77%)
At close: 03:59PM EDT
2.2200 0.00 (0.00%)
After hours: 06:38PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.2600
Open2.2100
Bid2.2200 x 1100
Ask2.3100 x 800
Day's Range2.2050 - 2.3599
52 Week Range2.1100 - 16.8000
Volume36,137
Avg. Volume102,315
Market Cap10.891M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.2900
Earnings DateMay 30, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FRLN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Freeline to Present at 2023 Jefferies Healthcare Conference

    LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023. The presentation will take place at 8 a.m. ET on June 9, 2023. Senior management will also participate in one-on-one investor meetings during the conference. A live webcast of the presentation will be available on the Investors section of Freeli

  • GlobeNewswire

    Freeline Reports First Quarter 2023 Financial Results and Business Highlights

    Expect to report initial clinical data for FLT201 in Gaucher disease in third quarter of 2023 FLT201 granted ILAP designation, which aims to accelerate time to market and facilitate patient access in the UK for medicines that address significant unmet needs Regained compliance with Nasdaq listing requirements LONDON, May 30, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the first quarter of 2023 and provided a business update. “FL

  • GlobeNewswire

    Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

    LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative Licensing and Access Pathway (ILAP) process by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the first step in the ILAP process, which in collaboration with MHRA and partner agencies, aims to accelerate time to market and fac

  • Simply Wall St.

    Both private equity firms who control a good portion of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) along with institutions must be dismayed after last week's 11% decrease

    Key Insights Significant control over Freeline Therapeutics Holdings by private equity firms implies that the general...

  • GlobeNewswire

    Freeline Completes ADS Ratio Change

    LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company’s previously disclosed change to its American Depositary Share (“ADS”) to ordinary share ratio has been made effective prior to the open of business on May 12, 2023. The ratio has changed from one (1) ADS to one (1) ordinary share to the new ratio of one (1) ADS to fifteen (15) ordinary shares. For the company’s ADS holders, the change in the ADS ratio has the same effect a

  • GlobeNewswire

    Freeline Announces Proposed ADS Ratio Change

    LONDON, April 21, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value £0.00001 per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to fifteen (15) ordinary shares (the “ADS Ratio Change”). The company anticipates that the ADS Ratio Change will be effective on or abou

  • GlobeNewswire

    Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference

    LONDON, April 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023. The presentation will take place at 8 a.m. ET on April 19, 2023. Senior management will also participate in one-on-one investor meetings during the conference. A live webcast of the presentation will be available on the Investors section of

  • Insider Monkey

    Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q4 2022 Earnings Call Transcript

    Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q4 2022 Earnings Call Transcript April 4, 2023 Operator: Good day, everyone. Welcome to the Freeline Therapeutics Business Update Conference Call. At this time, all participants are in listen-only mode. After the company’s prepared remarks, there will be a question-and-answer session. Please be advised that today’s conference call is being […]

  • Benzinga

    Freeline Therapeutics Announces Second Round Of Layoffs, Shelves Fabry Disease Program

    Freeline Therapeutics Holdings plc (NASDAQ: FRLN) further assessed its strategic priorities and decided to pause the development of FLT190 in Fabry disease to focus its resources on advancing FLT201, which has the potential to be a first- and best-in-class gene therapy for Gaucher disease type 1. Based on its preclinical data, Freeline believes FLT201 can potentially improve clinical outcomes for patients with Gaucher disease type 1 with a one-time therapy. The company is actively screening pati

  • GlobeNewswire

    Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update

    Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring organization and pausing development of FLT190 to extend cash runway into Q2 2024 Appointed CFO Paul Schneider to Board of Directors Management to host conference call today at 8 a.m. ET LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial res

  • GlobeNewswire

    Freeline Therapeutics to Host Full Year 2022 Financial Results Call

    LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022 financial results and provide a corporate update. To access the conference call, participants may register here. While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be ava

  • GlobeNewswire

    Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

    LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd., for $25 million, subject to purchase price adjustments. Concurrent with the closing, Freeline and Ascend entered into an intellectual property agreement that assigned certain intellectual pro

  • GlobeNewswire

    Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 81,000 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration c

  • GlobeNewswire

    Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

    Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in MARVEL-1 Phase 1/2 clinical trial LONDON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a

  • GlobeNewswire

    Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration

  • Simply Wall St.

    We're A Little Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • GlobeNewswire

    Freeline Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30, 2022. The Company will continue to trade

  • Benzinga

    Freeline Therapeutics Stops Further Development On Hemophilia Program, Cuts Workforce

    Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has decided to focus its resources on FLT201 in Gaucher disease and FLT190 in Fabry disease. The company will stop investment in further development of FLT180a without a partner. Additionally, Freeline announced updated data from the two patients treated in the first cohort from the MARVEL-1 Phase 1/2 trial of FLT190 at a dose of 7.5e11 vg/kg. People with classic Fabry disease have little to no functional α-Gal A enzyme. Data exhibited elevated α

  • GlobeNewswire

    Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

    Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizing development of FLT201 in Gaucher disease and FLT190 in Fabry disease; ceasing investment in further development of FLT180a in hemophilia B Updated data from first cohort of MARVEL-1 trial show FLT190 continues to be well-toler

  • GlobeNewswire

    Freeline to Present at the Stifel Healthcare Conference

    LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York. The fireside chat will take place on November 16th at 8:35 am ET. Senior management will also participate in one-on-one investor meetings during the conference. A live webcast of the fireside chat will be available on the Investors section of Freeline’

  • GlobeNewswire

    Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration

  • GlobeNewswire

    Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 416,850 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remunerati

  • GlobeNewswire

    Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

    LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency. “We believe FLT190 has the potential to be a life-changing therapy for people

  • GlobeNewswire

    Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Freeline Announces Inducement GrantsLONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 64,050 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independen

  • Zacks

    Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could Find Support Soon, Here's Why You Should Buy the Stock Now

    After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.